摘要
变活霉素A为一新的蒽环类广谱抗病毒抗生素,在组织培养内对4株单纯疱疹Ⅰ型病毒(HSV-1),4株单纯疱疹Ⅱ型病毒,流感甲_3病毒及柯萨奇B_6病毒的致细胞病变作用均有抑制活性,IC_(50)为6.25～12.5μg/ml。相同剂量可降低HSV-1繁殖量 1.5～3.5个对数值(log10)。细胞感染HSV-1后 4～10小时再用变活霉素A处理,仍可抑制,推迟细胞病变的发展.250～500μg/ml变活霉素A在无细胞系统内对HSV-2 DNA聚合酶,人免疫缺陷病毒(HIV-1)逆转录酶,鸭乙型肝炎病毒DNA聚合酶及牛胸腺DNA聚合酶α均无抑制活性。
Mutactimycin A is a new anthracycline antibiotic with broad-spectrum of antivirus activity. Mutactimycin A is produced by a original nonactive streptomyces mutated by activating silent genes.In tissue culture mutactimycin A inhibits the cytopathogenic effect of herpes simplex virus-l(4 strains), herpes simplex virus-2(4 strains), influenza virus A3(H3N2), coxsackie virus B6 with IC50 6.25-12.5μg/ml. The same doses can reduce the herpes simplex virus-1 virus yield by 1.5-3.5 log10.The inhibition of cytopathogenic effect of HSV-1 can also be observed when the treatment was started at 4-10 hours after infection. 250-500 μg/ml mutactimycin A doesnot show any effects on HSV-2 DNA polymerase, cloned human immunodeficiency virus reverse transcri-ptase, duck hepatitis B virus DNA polymerase and calf thymus DNA polymerase α in cell-free systems.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
1990年第3期170-174,共5页
Chinese Journal of Antibiotics
基金
国家医药管理局新药基金的资助
关键词
抗病毒抗生素
变活霉素A
病毒化疗
Mutactimycin A
Antiviral antibiotic
Herpes simplex viruses
Virus cemotherapy
